Ultragenyx Agrees to Sell a Priority Review Voucher for $210 Million

Ultragenyx has agreed to sell its Rare Pediatric Disease Priority Review Voucher for $210 million, according to a company announcement dated October 7, 2026. What was announced is an agreement to sell, not a completed transfer.

A priority review voucher is a transferable credential. Its holder can apply it to a future marketing application, which asks the U.S. Food and Drug Administration (FDA) to review that application on a priority timeline. A developer with no near-term filing that needs the faster clock can monetize the voucher. For a buyer, usually a drug company with its own application in the pipeline, the value lies in the review time it can compress and the earlier launch that could follow.

The price is the figure most worth holding against the historical record. In January 2021, Fierce Biotech reported that Alexion had paid $100 million for Rhythm's priority review voucher. The Ultragenyx figure is more than double that. The two data points are nearly six years apart and involve different sellers, buyers, and drug programs, so they should not be read as a price index. Still, the disclosed number gives a reader tracking voucher prices a recent anchor.

Earlier, AstraZeneca agreed to buy a U.S. Food and Drug Administration priority review voucher from Sobi in August 2019. That trade shows voucher sales are not new. The facts available here do not include its price, so it cannot serve as a comparison point for the $210 million figure.

Several things set a voucher's worth, and a headline number folds them into one. The first is timing. A voucher's usefulness depends on when a buyer expects to file, because its value falls if the application it would accelerate is years away or has already cleared review. The second is the buyer's portfolio economics. Each day of review time saved is worth more to a company launching a blockbuster than to one launching a niche product. The third is the seller's alternatives. A company holding a voucher it does not need can sell now or keep the option, and the price reflects where each party thinks that option lies.

For savers and investors, the more useful question is what a sale like this says about how rare pediatric drug developers finance their work. A voucher sale converts a regulatory benefit into cash without a product approval, a trial readout, or a partnership. That makes it a source of non-dilutive funding, meaning money raised without issuing new shares and so without diluting existing owners' stakes. The cash flows to the seller. The broader signal is that a credential tied to regulatory timing now carries a public market price, at least for one recent transaction.

In my view, caution is warranted. An agreement announced in October is not a closed sale, and a single price, however large, does not establish a trend. Anyone modeling future voucher prices needs the pending application pipeline of likely buyers, the timing of their filings, and the number of vouchers competing for those buyers. The company-stated price is a dated fact. The rest is inference.